Biospecimen Collection (NCT06917911)

Name: Biospecimen Collection trial for Core Binding Factor Acute Myeloid Leukemia (NCT06917911)
Uploaded: 2026-10-31T05:26:01.275Z
Duration: 1 min 34 s
Description: Biospecimen Collection trial for Core Binding Factor Acute Myeloid Leukemia (NCT06917911). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06917911.

Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial): a one-minute explainerNCT069179111 min

Biospecimen Collection trial for Core Binding Factor Acute Myeloid Leukemia (NCT06917911). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults aged 18–59 with newly diagnosed core-binding-factor acute myeloid leukemia, without FLT3 mutations, assigned through myeloMATCH.

The idea: compare oral venetoclax with intravenous gemtuzumab ozogamicin, each added to cytarabine and daunorubicin chemotherapy. Venetoclax blocks a protein that supports cancer-cell survival. Gemtuzumab ozogamicin delivers a DNA-damaging drug to CD33-bearing cells. Researchers compare remission without measurable residual disease.

This phase 2 study plans 162 patients. Celalettin Ustun leads through the Alliance for Clinical Trials in Oncology; 77 US locations list recruitment.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.